LRI Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

LRI Investments’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.37K	Sell	7 -9	-56%	-$6.13K	﹤0.01%	1164
2026 Q1	$12.4K	Buy	16 +12	+300%	+$9.19K	﹤0.01%	825
2025 Q4	$3.09K	Hold	4	–	–	﹤0.01%	1135
2025 Q3	$2.25K	Hold	4	–	–	﹤0.01%	1185
2025 Q2	$2.1K	Hold	4	–	–	﹤0.01%	1162
2025 Q1	$2.54K	Sell	4 -44	-92%	-$30.3K	﹤0.01%	1073
2024 Q4	$34.4K	Sell	48 -127	-73%	-$107K	﹤0.01%	582
2024 Q3	$137K	Sell	175 -74	-30%	-$82.4K	0.01%	350
2024 Q2	$261K	Buy	249 +245	+6,125%	+$238K	0.03%	202
2024 Q1	$3.85K	Buy	+4	New	+$3.8K	﹤0.01%	670

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MCI

McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

LRI Investments's REGN Position: Q2 2026 in Review

LRI Investments reduced its Regeneron Pharmaceuticals (REGN) stake by 56% in Q2 2026, selling an estimated $6.13K and leaving 7 shares worth $4.37K. The position accounts for ﹤0.01% of the portfolio, ranked #1164.

LRI Investments first reported a position in REGN in Q1 2024 and has held it in 10 quarters since. The position peaked at $261K in Q2 2024. 518 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

LRI Investments held 7 shares of Regeneron Pharmaceuticals worth $4.37K as of Q2 2026.
LRI Investments sold 9 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $6.13K.
Regeneron Pharmaceuticals made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #1164 holding.
LRI Investments first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
LRI Investments's Regeneron Pharmaceuticals position peaked at $261K in Q2 2024.
518 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.